A researcher from Stanford University in the United States tested the effects of lisiprinol on mice with multiple sclerosis and found a regression of their paralysis.
This molecule, which is part of the family of converting enzyme inhibitors, also made it possible to prevent the disease in mice which were not yet affected by the disease,
However, it remains to be seen whether these results will be confirmed in humans; research will therefore turn to inhibitors of the converting enzyme.
Multiple sclerosis, a disease of the central nervous system, affects around 70,000 people in France. It is manifested by motor and vision disorders, sensory and neurological disorders.
